Early changes in proteoglycans production by resistance arteries smooth muscle cells of hypertensive rats.
Several functional and structural modifications at the vascular level have been described in spontaneously hypertensive rats (SHR) during the early development of hypertension. In this study, we hypothesize that changes in the extracellular matrix (ECM) could precede the development of hypertension. Synthesis of secreted and membrane-bound sulfated proteoglycans (S-PG) by cultured vascular smooth muscle cells (VSMC) obtained from young spontaneously hypertensive rats (pSHR) mesenteric resistance arteries, during the period preceding the elevation of blood pressure (BP) was tested. After 24 h of stimulation with angiotensin II (Ang II), 10% fetal calf serum (FCS), or 0.1% FCS as control, medium and cell layer S-PG synthesis was evaluated by labeling sulfated disaccharides with [35S] sodium sulfate. To relate this variable with cell proliferation, DNA synthesis was measured by incorporation of [3H]thymidine in the cell lysate. The VSMC from pSHR synthesized more secreted and membrane-bound S-PG than age-matched Wistar rat (pW) cells in the nonstimulated (0.1% FCS) and stimulated (Ang II or 10% FCS) experimental groups. When data were expressed as percent of their own control value, both Ang II and 10% FCS lowered basal secreted and cell-associated S-PG content in VSMC from pSHR, whereas in pW rat cells, these agents produced a small increase or no change. An inverse relationship between proliferation and total S-PG production (secreted plus membrane-bound) was found in pSHR cells, but not in pW cells. In conclusion, the present study demonstrates that changes in S-PG synthesis by VSMC of resistance arteries precede the vascular dysfunction associated with the development of hypertension in SHR.
Risler
Norma
N
Department of Pathology, School of Medicine, National University of Cuyo, Mendoza, Argentina. nrisler@fmed2.uncu.edu.ar
Castro
Claudia
C
Cruzado
Montserrat
M
González
Susana
S
Miatello
Roberto
R
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D002417:Cattle / Q000097:blood / Q000196:embryology; D002455:Cell Division; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D005312:Fetal Blood; D006973:Hypertension / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008638:Mesenteric Arteries / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D009131:Muscle, Smooth, Vascular / Q000378:metabolism* / Q000473:pathology; D011509:Proteoglycans / Q000096:biosynthesis*; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D014655:Vascular Resistance
D011509:Proteoglycans; D000804:Angiotensin II; D004247:DNA